Compare FMST & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMST | FEMY |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 30.2M |
| IPO Year | N/A | 2021 |
| Metric | FMST | FEMY |
|---|---|---|
| Price | $3.06 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 247.7K | ★ 4.1M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $0.55 | $0.31 |
| 52 Week High | $5.74 | $1.80 |
| Indicator | FMST | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 55.49 |
| Support Level | $2.64 | $0.83 |
| Resistance Level | $3.03 | $1.03 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 99.19 | 63.17 |
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.